Actinium Pharmaceuticals

ATNM

Market cap $27.7M

ATNM Hedge Fund Activity: Q1 2026 in Review

54 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2026, worth a combined $5.27M — down 28% from $7.36M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ATNM and 7 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 12 added.

The largest buyer was Two Sigma Investments, adding an estimated $152K. The largest seller was Squarepoint, exiting entirely with an estimated $89.4K sold.

• 54 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2026, down from 60 in Q4 2025.
• Funds reported $5.27M of Actinium Pharmaceuticals stock for Q1 2026, down 28% quarter-over-quarter.
• 7 funds opened new Actinium Pharmaceuticals positions in Q1 2026 and 12 closed out, a net change of -5 holders.
• The largest Actinium Pharmaceuticals buyer in Q1 2026 was Two Sigma Investments, an estimated $152K added.
• The largest Actinium Pharmaceuticals seller in Q1 2026 was Squarepoint, an estimated $89.4K sold.

Based on aggregated 13F filings for Q1 2026.